Search hospitals

>

New York

>

New York

NYU Langone Health

Claim this profile

New York, New York 10016

Global Leader in Lung Cancer

Global Leader in Cancer

Conducts research for Pancreatic Cancer

Conducts research for Breast Cancer

Conducts research for Solid Tumors

658 reported clinical trials

260 medical researchers

Photo of NYU Langone Health in New YorkPhoto of NYU Langone Health in New YorkPhoto of NYU Langone Health in New York

Summary

NYU Langone Health is a medical facility located in New York, New York. This center is recognized for care of Lung Cancer, Cancer, Pancreatic Cancer, Breast Cancer, Solid Tumors and other specialties. NYU Langone Health is involved with conducting 658 clinical trials across 1,745 conditions. There are 260 research doctors associated with this hospital, such as Sharon L. Gardner, Paul Oberstein, MD, Bhavana Pothuri, and Vamsidhar Velcheti, MD.

Area of expertise

1

Lung Cancer

Global Leader

NYU Langone Health has run 84 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
EGFR positive
2

Cancer

Global Leader

NYU Langone Health has run 78 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage III
FGFR3 positive

Top PIs

Clinical Trials running at NYU Langone Health

Colorectal Cancer

Lung Cancer

Cancer

Breast Cancer

Pancreatic Cancer

Mesothelioma

Lazy Eye

Heart Attack

Ovarian Cancer

Kidney Cancer

Image of trial facility.

Pancreatic Cancer Screening

for Pancreatic Cancer

This trial is overseen by Johns Hopkins clinical research office. Team members at each location will report any major issues to the lead researcher.

Recruiting

2 awards

Phase 3

2 criteria

Image of trial facility.

A2B395 CAR T-Cell Therapy

for Colorectal Cancer

The goal of this study is to test A2B395, an allogeneic logic-gated Tmodâ„¢ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), renal cell carcinoma (RCC) and other solid tumors that express EGFR and have lost HLA-A\*02 expression. The main questions this study aims to answer are: * Phase 1: What is the recommended dose of A2B395 that is safe for patients * Phase 2: Does the recommended dose of A2B395 kill the solid tumor cells and protect the patient's healthy cells Participants will be required to perform study procedures and assessments, and will also receive the following study treatments: * Enrollment in BASECAMP-1 (NCT04981119) * Preconditioning lymphodepletion (PCLD) regimen * A2B395 Tmod CAR T cells at the assigned dose

Recruiting

1 award

Phase 1 & 2

4 criteria

Image of trial facility.

A2B694 CAR T-Cells

for Solid Cancers

This trial tests a new immune cell therapy for adults with difficult-to-treat solid tumors. The therapy modifies the patient's own immune cells to target and kill cancer cells while protecting healthy cells. The study aims to find a safe dose and see how well it works.

Recruiting

1 award

Phase 1 & 2

7 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at NYU Langone Health?

Where is NYU Langone Health located?

Who should I call to ask about financial aid or insurance network?

What insurance does NYU Langone Health accept?

What awards or recognition has NYU Langone Health received?